Advocacy intelligence hub — real-time data for patient organizations
Centre Oscar Lambret — NA
Massachusetts General Hospital — PHASE2
Institute of Hematology & Blood Diseases Hospital, China
Second Affiliated Hospital, School of Medicine, Zhejiang University — PHASE2
AbbVie
Beijing Biotech — PHASE1, PHASE2
Essen Biotech — PHASE1, PHASE2
Tongji Hospital
AbbVie — PHASE2
Sciensano — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Elahere
ImmunoGen, Inc.
Elahere
(mirvetuximab soravtansine-gynx)Orphan drugstandardImmunoGen, Inc.
12.1 Mechanism of Action Mirvetuximab soravtansine-gynx is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against folate r...
Rubraca
(rucaparib)Orphan drugstandardpharma&
12.1 Mechanism of Action Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a ...
Zejula
(niraparib)Orphan drugstandardGlaxoSmithKline, LLC.
12.1 Mechanism of Action Niraparib is an inhibitor of PARP enzymes, including PARP-1 and PARP-2, that play a role in DNA repair. In vitro studies have...
Avastin
(bevacizumab)Orphan drugstandardGenentech, Inc.
Vascular Endothelial Growth Factor Inhibitor [EPC]
12.1 Mechanism of Action Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial ce...
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
Epithelial ovarian cancer frequently recurs and becomes resistant to platinum chemotherapy. We investigated whether adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, improves pro...
Ileocecal and Small Bowel Involvement Are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma.
Complete macroscopic tumor resection is the strongest prognostic factor in advanced epithelial tubo-ovarian and primary peritoneal cancer, yet benefit from maximum-effort cytoreductive surgery may var...
Primary Peritoneal Low-Grade Serous Carcinoma in a 16-Year-Old Female: A Case Report.
Background : Primary peritoneal carcinoma (PPC) is an uncommon malignancy typically diagnosed in postmenopausal women, accounting for less than 1% of all gynecologic cancers. Its occurrence in adolesc...
Heterogeneity in Stage IV Ovarian Cancer: Survival Trends in Patients Presenting with Sister Mary Joseph's Nodule.
Background/Objectives : Sister Mary Joseph's nodule (SMJN) is classified as FIGO stage IVb in ovarian cancer. While traditionally considered an indicator of poor prognosis, emerging evidence suggests ...
A retrospective analysis of risk-reducing salpingo-oophorectomy performed in women diagnosed with hereditary breast and ovarian cancer at our institution.
Hereditary breast and ovarian cancer (HBOC) confers a markedly increased lifetime risk of breast and ovarian cancers. As no effective surveillance method for early detection of ovarian cancer has been...
Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial.
Epigenetic modulators may sensitize platinum-resistant ovarian cancer (PROC) to immune checkpoint inhibition by reprogramming the tumor microenvironment. We report clinical and translational findings ...
David M Gershenson, M.D
NRG Oncology
📍 HOUSTON, TX
Amir A. Jazaeri, MD, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Don Dizon, MD
NRG Oncology
📍 PROVIDENCE, RI
Robert L Coleman
NRG Oncology
📍 Anchorage, Alaska
Martee Hensley, MD
Gynecologic Oncology Group
📍 NEW YORK, NY
Bradley Monk, MD
Gynecologic Oncology Group
📍 WEST PALM BEACH, FL